---
title: "Obefazimod (ABX464) in Ulcerative colitis: Interleukin-23 p19 inhibitors"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Interleukin-23 p19 inhibitors. Topics: ACG 2025 guideline: recommendations for induction and maintenance, Pivotal trial results for guselkumab and mirikizumab: ACG 2025 evidence summary, Comparison with ustekinumab and switching within the class: ACG 2025, ECCO 2026 guideline: recommendations and risankizumab trial results, and 4 further topics. 8 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/interleukin-23-p19-inhibitors"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Interleukin-23 p19 inhibitors

<a id="heading-2.2.2.1.7"></a>

## 2.2.2.1.7 Interleukin-23 p19 Inhibitors

<a id="topic-2.2.2.1.7-1"></a>

### ACG 2025 guideline: recommendations for induction and maintenance

> “In patients with moderately to severely active UC, we recommend the IL23p19 inhibitor guselkumab, mirikizumab, or risankizumab for induction of remission (Strong recommendation, moderate quality of evidence).”
> “We recommend continuing guselkumab, mirikizumab, or risankizumab as compared with no treatment for maintenance of remission in patients who respond to the induction dosing of the same treatment (Strong recommendation, moderate quality of evidence).”
> “Guselkumab, mirikizumab, and risankizumab are monoclonal antibodies that target the p19 subunit of IL-23 and are approved for the treatment of moderately to severely active UC.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.7-2"></a>

### Pivotal trial results for guselkumab and mirikizumab: ACG 2025 evidence summary

> “In the phase 3 study, guselkumab 200 mg IV at weeks 0, 4, and 8 demonstrated that a significantly greater proportion of clinical remission compared with placebo at week 12 (22.6% vs 7.9%, adjusted ∆ = 14.9%, P < 0.001)”
> “Clinical remission at maintenance week 44 was significantly greater with SC guselkumab 200 mg q4w (50.0% [95/190]; 29.5%, 20.9–38.1) and 100 mg q8w (45.2% [85/188]; 25.2%, 26.4–33.9) compared with placebo (18.9% [36/190]) (both P < 0.001).”
> “In the induction trial, 24.2% of patients receiving mirikizumab achieved clinical remission compared with 13.3% of patients receiving placebo (P < 0.001).”
> “At the end of an additional 40 weeks of maintenance, nearly half (49.9%) of patients receiving mirikizumab achieved clinical remission compared with 25.1% receiving placebo (P < 0.001)”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.7-3"></a>

### Comparison with ustekinumab and switching within the class: ACG 2025

> “There are prospective comparative trials demonstrating superiority of 2 of the p19 therapies (guselkumab and risankizumab) in patients with moderately to severely active CD, but no such data exist for moderately to severely active UC. In addition, there are no data on cycling within the class of IL23p19 drugs.”
> “Some patients with moderately to severely active UC who are at higher risk for infectious complications may benefit from vedolizumab or an anti-IL-23 strategy over more systemically immunosuppressive medical options.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.7-4"></a>

### ECCO 2026 guideline: recommendations and risankizumab trial results

> “We recommend treatment with mirikizumab for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, moderate certainty of evidence] [Agreement: 100%]”
> “We recommend treatment with risankizumab for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, moderate certainty of evidence] [Agreement: 100%]”
> “We recommend treatment with guselkumab for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, moderate certainty of evidence] [Agreement: 100%]”
> “At week 12, risankizumab significantly improved clinical remission rates compared with placebo (20.3% vs 6.2%, respectively; adjusted between-group difference [BGD]: 14.0% [95% CI: 10.0–18.0%]; P < .001).”
> “In the maintenance trial, each dose of risankizumab significantly improved clinical remission rates compared with placebo (40.2% for 180 mg risankizumab and 37.6% for 360 mg risankizumab vs 25.1% for placebo, BGD for 180 mg risankizumab vs placebo: 16.3% [95% CI: 6.1–26.6%]; P < .001)”
> “SC guselkumab is also effective for induction of remission in UC; this indication is supported by the efficacy and safety results from the ASTRO program.”
> “Data for IL-23 antagonist dose escalation are minimal and require further evidence before broader implementation.”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.7-5"></a>

### Network meta-analyses: rankings of interleukin-23 p19 inhibitors

> “Ater excluding JAK inhibitors, amongst biologic-naïve patients with moderately to severely active UC, risankizumab (P-score 0.86) and ozanimod (P-score 0.83) were ranked highest for induction of clinical remission (Figure 1b).”

Source: [Ananthakrishnan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12148344/)

> “Risankizumab ranked first in the induction of histological remission (89.4%), followed by guselkumab (88.3%).”

Source: [Shehab et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39182898/)

> “Anti-p19 inhibitors, including risankizumab, subcutaneous guselkumab, and mirikizumab, were associated with the most favorable safety profiles for serious adverse events and adverse events leading to discontinuation, although confidence in safety estimates was lower.”

Source: [Olivera et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42838315/)

<a id="topic-2.2.2.1.7-6"></a>

### Mirikizumab: mechanism and dosing in ulcerative colitis

> “Mirikizumab-mrkz is a humanized IgG4 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor.”
> “Week 0, Week 4, and Week 8: Infuse 300 mg intravenously over at least 30 minutes”
> “Week 12 and every 4 weeks thereafter: Inject 200 mg subcutaneously (given as one injection of 200 mg or as two consecutive injections of 100 mg each)”

Source: [Omvoh prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761279s005lbl.pdf)

<a id="topic-2.2.2.1.7-7"></a>

### Risankizumab: mechanism and dosing in ulcerative colitis

> “Risankizumab-rzaa is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor.”
> “The recommended induction dosage of SKYRIZI is 1,200 mg administered by intravenous infusion over a period of at least two hours at Week 0, Week 4, and Week 8”
> “The recommended maintenance dosage of SKYRIZI is 180 mg or 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter.”

Source: [Skyrizi prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761105s053lbl.pdf)

<a id="topic-2.2.2.1.7-8"></a>

### Guselkumab: mechanism and dosing in ulcerative colitis

> “Guselkumab is a human monoclonal IgG1λ antibody that selectively binds to the p19 subunit of interleukin 23 (IL-23) and inhibits its interaction with the IL-23 receptor.”
> “200 mg administered by intravenous infusion over at least one hour at Week 0, Week 4, and Week 8”
> “400 mg administered by subcutaneous injection (given as two consecutive injections of 200 mg each) at Week 0, Week 4, and Week 8.”
> “100 mg administered by subcutaneous injection at Week 16, and every 8 weeks thereafter, or”

Source: [Tremfya prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761061s034lbl.pdf)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
